Subsequent Primary Cancer Diagnoses Among Patients With Neuroendocrine Tumors - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Risk of Subsequent Primary Cancers in Patients Diagnosed With Neuroendocrine Tumors

  • By

  • Manas Pustake

  • Charles W. Shi

  • Matthew T. Gao

  • Nicholas J. Hornstein

  • Seth J. Concors

  • Timothy J. Brown

  • Udhayvir S. Grewal

  • November 16, 2026

Share

Clinical Scorecard: Risk of Subsequent Primary Cancers in Patients Diagnosed With Neuroendocrine Tumors

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Risk of Subsequent Primary Cancers in Patients Diagnosed With Neuroendocrine Tumors
Key MechanismsAnalytic approach: time-varying Fine-Gray competing-risk models treated death before SPC as a competing event.
Target PopulationPopulation described in the source article.
Care SettingCare setting described in the source article.

Key Highlights

  • During a median 47-month follow-up, 7.41% of the cohort developed an SPC.
  • SPCs occurred in 4.97% of patients with early-onset NETs and 8.06% of those with average-onset NETs.
  • Adjusted SPC subdistribution hazard ratios for early-onset versus average-onset NET were 0.35 at 1 year, 0.59 at 5 years, and 0.73 at 10 years.
  • Among patients with early-onset NET, gastric, pancreatic, and small-intestinal primary sites were associated with higher SPC risk; appendiceal NETs were associated with lower risk.
  • The authors state that these findings do not support modifying established population-based cancer screening recommendations.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • The authors state that future survivorship strategies may need to account for demographic and disease-specific features associated with SPC occurrence.

      Risks

        Patient & Prescribing Data

        Registry cohort of 95,625 patients with NETs diagnosed from 2000 through 2021; 20,119 (21.04%) had early-onset disease, defined as age younger than 50 years.

        The study evaluated SPC risk and did not report treatment or prescribing comparisons.

        Clinical Best Practices

        • The adjusted relative subdistribution hazard for early-onset versus average-onset NET increased from 0.35 at 1 year to 0.73 at 10 years.
        • Among patients with early-onset NET, gastric, pancreatic, and small-intestinal primary sites were associated with higher SPC risk, while appendiceal NETs were associated with lower risk.
        • The authors state that the findings do not support modifying established population-based cancer screening recommendations; site-specific incidence was not compared with the general population.

        Related Resources & Content

          Original Source(s)

          Related Content